These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11967726)

  • 21. Role of oxidative stress in angiotensin-II mediated contraction of human conduit arteries in patients with cardiovascular disease.
    Püntmann VO; Hussain MB; Mayr M; Xu Q; Singer DR
    Vascul Pharmacol; 2005 Oct; 43(4):277-82. PubMed ID: 16243586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases.
    Patel BM; Mehta AA
    Eur J Pharmacol; 2012 Dec; 697(1-3):1-12. PubMed ID: 23041273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor.
    Flesch M; Höper A; Dell'Italia L; Evans K; Bond R; Peshock R; Diwan A; Brinsa TA; Wei CC; Sivasubramanian N; Spinale FG; Mann DL
    Circulation; 2003 Aug; 108(5):598-604. PubMed ID: 12874189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
    Jorde UP; Vittorio TJ; Dimayuga CA; Homma S; Rizkala A; Le Jemtel TH; Katz SD
    Am J Cardiol; 2004 Dec; 94(12):1501-5. PubMed ID: 15589004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
    Whaley-Connell A; Pavey BS; Chaudhary K; Saab G; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease.
    Mancia G; Dell'Oro R; Quarti-Trevano F; Scopelliti F; Grassi G
    J Hypertens Suppl; 2006 Mar; 24(1):S51-6. PubMed ID: 16601574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aldosterone and cardiovascular diseases, more than water and salt retention].
    Duprez D
    Verh K Acad Geneeskd Belg; 2002; 64(3):225-32. PubMed ID: 12238244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis.
    Fukuda D; Sata M
    Pharmacol Ther; 2008 May; 118(2):268-76. PubMed ID: 18439685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart failure, platelet activation and inhibition of the renin-angiotensin-aldosterone system.
    Bauersachs J; Schäfer A
    Arch Mal Coeur Vaiss; 2004 Sep; 97(9):889-93. PubMed ID: 15521482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J
    Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of hormone therapy on blood pressure and the renin-angiotensin system in postmenopausal women.
    Prime DD; Brosnihan KB; Herrington DM
    Minerva Cardioangiol; 2007 Aug; 55(4):477-85. PubMed ID: 17653023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist.
    Haddad GE; Blackwell K; Bikhazi A
    Can J Physiol Pharmacol; 2003 Feb; 81(2):142-9. PubMed ID: 12710528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the AT1 angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor?
    Hunyady L; Turu G
    Trends Endocrinol Metab; 2004 Nov; 15(9):405-8. PubMed ID: 15519886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin-angiotensin system and haemostasis gene polymorphisms and outcome after coronary artery bypass graft surgery.
    Völzke H; Kleine V; Robinson DM; Grimm R; Hertwig S; Schwahn C; Eckel L; Rettig R
    Int J Cardiol; 2005 Jan; 98(1):133-9. PubMed ID: 15676177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sleep apnea syndromes and cardiovascular disease].
    Bounhoure JP; Galinier M; Didier A; Leophonte P
    Bull Acad Natl Med; 2005 Mar; 189(3):445-59; discussion 460-4. PubMed ID: 16149210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects.
    Raizada V; Skipper B; Luo W; Griffith J
    J Investig Med; 2007 Nov; 55(7):341-59. PubMed ID: 18062896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The renin-angiotensin system and the heart: beyond 2000.
    Morgan T; Brunner HR
    Heart; 1996 Nov; 76(3 Suppl 3):98-103. PubMed ID: 8983669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The cardiac autocrine-paracrine system in the development of hypertrophy].
    Neri Serneri GG; Modesti PA; Boddi M
    Cardiologia; 1997 Jan; 42(1):11-9. PubMed ID: 9118150
    [No Abstract]   [Full Text] [Related]  

  • 40. Renin-angiotensin aldosteron system (RAAS) and the cardiovascular risks.
    Singh RB
    Indian Heart J; 2000; 52(3):358-9. PubMed ID: 10976164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.